Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian C Marschner

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
BJU International|November 5, 2025
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerYu Yang Soon, Ian C Marschner, I Manjula Schou, et al.
JAMA Network Open|September 17, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate CancerYu Yang Soon, Ian C Marschner, Manjula Schou, et al.
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
Resuscitation|January 31, 2026
ECPR eligible refractory out of hospital cardiac arrests - a post-hoc analysis of the EVIDENCE Randomised Controlled Trial and RegistryMiles Greenberg, Brian Burns, Patrick Lay, et al.
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.
European Journal of Endocrinology|July 5, 2023
Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trialKristy P Robledo, Ian C Marschner, David J Handelsman, et al.
Respirology (Carlton, Vic.)|October 7, 2025
Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised TrialPeter Wark, Ian C Marschner, Owen Hutchings, et al.
American Heart Journal|June 24, 2010
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trialR John Simes, Rachel L O'Connell, Philip E Aylward, et al.
Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
BJU International|November 5, 2025
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerYu Yang Soon, Ian C Marschner, I Manjula Schou, et al.
JAMA Network Open|September 17, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate CancerYu Yang Soon, Ian C Marschner, Manjula Schou, et al.
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
Resuscitation|January 31, 2026
ECPR eligible refractory out of hospital cardiac arrests - a post-hoc analysis of the EVIDENCE Randomised Controlled Trial and RegistryMiles Greenberg, Brian Burns, Patrick Lay, et al.
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.
European Journal of Endocrinology|July 5, 2023
Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trialKristy P Robledo, Ian C Marschner, David J Handelsman, et al.
Respirology (Carlton, Vic.)|October 7, 2025
Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised TrialPeter Wark, Ian C Marschner, Owen Hutchings, et al.
American Heart Journal|June 24, 2010
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trialR John Simes, Rachel L O'Connell, Philip E Aylward, et al.
Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.
Pageof 6